Big peer collaboration, once a rare bird in the biopharma industry, has become more pervasive and necessary, in part due to overcapacity with too many companies chasing the same goals, and in part due to the opportunity to share risks and costs.
The observation, while not news to the industry per se, arouses interest because it came from Shaun Grady and Roger...